HSIC

Henry Schein Inc
NASDAQHEALTHCAREMEDICAL DISTRIBUTION

Key Statistics

Market Cap
$9.84B
P/E Ratio
25.18
EPS
$3.43
Beta
0.81
52W High
$92.18
52W Low
$61.95
50-Day MA
$87.84
200-Day MA
$79.97
Dividend Yield
—
Profit Margin
2.96%
Forward P/E
14.81
PEG Ratio
1.74

About Henry Schein Inc

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$13.60B
Gross Profit (TTM)$4.26B
EBITDA$1.08B
Operating Margin5.76%
Return on Equity8.85%
Return on Assets4.39%
Revenue/Share (TTM)$116.77
Book Value$28.21
Price-to-Book3.09
Price-to-Sales (TTM)0.72
EV/Revenue0.985
EV/EBITDA13.27
Quarterly Earnings Growth (YoY)17.10%
Quarterly Revenue Growth (YoY)6.70%
Shares Outstanding$113.92M
Float$91.71M
% Insiders0.83%
% Institutions112.28%

Historical Volatility

HV 10-Day
25.40%
HV 20-Day
21.74%
HV 30-Day
18.46%
HV 60-Day
20.42%
HV Rank
11.5%

Volatility is currently expanding

Analyst Ratings

Consensus ($97.27 target)
4
Strong Buy
5
Buy
7
Hold
1
Sell

Latest News

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research9/18/2026Positive
What Makes Henry Schein (HSIC) a New Buy Stock

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research9/16/2026Positive
HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research9/16/2026Neutral
Henry Schein: Growth Is Improving, But The Valuation Stays Cheap

Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic growth, margin expansion, and substantial share repurchases. Q2 2026 results showed 4.6% internal growth, 48 bps gross margin expansion, and a 6.7% reduction in diluted share count, signaling improved business quality. The BOLD+1 cost program targets $125M+ in annual run-rate operating income gains by end-2026, supporting double-digit earnings growth potential into 2027.

Seeking Alpha9/16/2026Positive
Henry Schein to Participate in Upcoming Investor Conference in September

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conference in September: Baird Global Healthcare Conference at the InterContinental Hotel, New York City on September 15, 2026, at 12:15 p.m. EDT. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on t.

Business Wire9/8/2026Neutral
HSIC vs. SAUHY: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research8/25/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HSIC and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/28/2026